Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
Center of Reproductive Medicine and Andrology, University Hospital of Muenster, Domagkstraße 11, 48149, Münster, Germany.
Anal Bioanal Chem. 2021 Sep;413(22):5655-5667. doi: 10.1007/s00216-021-03439-9. Epub 2021 Jun 18.
In order to detect the misuse of testosterone (T), urinary steroid concentrations and concentration ratios are quantified and monitored in a longitudinal manner to enable the identification of samples exhibiting atypical test results. These suspicious samples are then forwarded to isotope ratio mass spectrometry (IRMS)-based methods for confirmation. Especially concentration ratios like T over epitestosterone (E) or 5α-androstanediol over E proved to be valuable markers. Unfortunately, depending on the UGT2B17 genotype and/or the gender of the athlete, these markers may fail to provide evidence for T administrations when focusing exclusively on urine samples. In recent years, the potential of plasma steroids has been investigated and were found to be suitable to detect T administrations especially in female volunteers. A current drawback of this approach is the missing possibility to confirm that elevated steroid concentrations are solely derived from an administration of T and cannot be attributed to confounding factors. Therefore, an IRMS method for plasma steroids was developed and validated taking into account the comparably limited sample volume. As endogenous reference compounds, unconjugated cholesterol and dehydroepiandrosterone sulfate were found suitable, while androsterone and epiandrosterone (both sulfo-conjugated) were chosen as target analytes. The developed method is based on multi-dimensional gas chromatography coupled to IRMS in order to optimize the overall assay sensitivity. The approach was validated, and a reference population encompassing n = 65 males and females was investigated to calculate population-based thresholds. As proof-of-concept, samples from volunteers receiving T replacement therapies and excretion study samples were investigated.
为了检测睾酮(T)的滥用,采用纵向方式定量和监测尿中类固醇浓度和浓度比,以识别出现异常测试结果的样本。然后将这些可疑样本送到基于同位素比质谱(IRMS)的方法进行确认。特别是 T 与表睾酮(E)的比值或 5α-雄烷二醇与 E 的比值被证明是有价值的标志物。不幸的是,取决于 UGT2B17 基因型和/或运动员的性别,当仅关注尿液样本时,这些标志物可能无法为 T 给药提供证据。近年来,已经研究了血浆类固醇的潜力,并发现它们适合检测 T 给药,尤其是在女性志愿者中。这种方法的一个当前缺点是缺乏可能性来确认升高的类固醇浓度仅源自 T 的给药,并且不能归因于混杂因素。因此,开发了一种用于血浆类固醇的 IRMS 方法,并考虑到相对有限的样本量进行了验证。未结合胆固醇和脱氢表雄酮硫酸盐被选为内源性参考化合物,而雄酮和表雄酮(均为硫酸结合)被选为目标分析物。该方法基于多维气相色谱法与 IRMS 耦合,以优化整体分析灵敏度。该方法得到了验证,并对包括 n=65 名男性和女性的参考人群进行了研究,以计算基于人群的阈值。作为概念验证,研究了接受 T 替代治疗的志愿者的样本和排泄研究样本。